Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia

Clinical Infectious Diseases

Volumn 39, Issue SUPPL. 1, 2004, Pages

  Tamura, K ^a,i   Imajo, K ^b   Akiyama, N ^d   Sozuki, K ^e   Urabe, A ^f   Ohyashiki, K ^g   Tanimoto, M ^c   Masaoka, T ^h  

^a FUKUOKA UNIVERSITY HOSPITAL   (Japan)

^b Okayama Citizens Hospital   (Japan)

^c OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^d TOKYO METROPOLITAN BOKUTOH HOSPITAL   (Japan)

^e JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^f Kanto Teishin Hospital   (Japan)

^g TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^h OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

ⁱ FUKUOKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CARBAPENEM; CEFEPIME; ERYTHROMYCIN; GLYCOPEPTIDE; MEROPENEM; PANIPENEM; SULPERAZON;

APLASTIC ANEMIA; BACTERIAL INFECTION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; EMPIRICISM; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC DISEASE; HUMAN; KIDNEY DYSFUNCTION; LEUKEMIA; LIVER DYSFUNCTION; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; MYELOMA; NEUTROPHIL; NONHUMAN; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TREATMENT OUTCOME;

AMIKACIN; ANTINEOPLASTIC AGENTS; BACTEREMIA; CEPHALOSPORINS; DRUG THERAPY, COMBINATION; FEMALE; FEVER; HEMATOLOGIC DISEASES; HUMANS; IMMUNOCOMPROMISED HOST; JAPAN; LEUKEMIA; MALE; NEUTROPENIA; OPPORTUNISTIC INFECTIONS;

EID: 3242786240     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/383046     Document Type: Conference Paper

References (14)

1. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990; 161:381-96.
2. Masaoka T. Conclusions and recommendations: evidence-based recommendations on antimicrobial use in febrile neutropenia in Japan. Int J Hematol 1998; 68(Suppl 1):S39-40.
3. Hughes WT, Armstrong D, Bodey GP, et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997; 25:551-73.
4. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979:16-21.
5. Ramphal R, Gucalp R, Rotstein C, Cimino M, Oblon D. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient. Am J Med 1996; 100(Suppl 6A):83S-9S.
6. Klastersky JA. Treatment of neutropenic infection: trends towards monotherapy? In: Klastersky JA, eds. Febrile neutropenia. Berlin: Springer-Verlag, 1997:47-52.
7. Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315:552-8.
8. Winston DJ, Ho WG, Bruckner DA, Champlin RE. Beta-lactam antibiotic therapy in febrile granulocytopenic patients: a randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med 1991; 115:849-59.
9. Leyland MJ, Bayston KF, Cohen J, et al. A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies. J Antimicrob Chemother 1992; 30:843-53.
10. Tamura K, Matsuoka H, Tsukada J, et al. Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: comparative study. Am J Hematol 2002; 71:248-55.
11. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34:730-51.
12. Hughes WT, Pizzo PA, Wade JC, Armstrong D, Webb CD, Young LS. Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Clin Infect Dis 1992; 15(Suppl 1): S206-15.
13. Urabe A, Toyama K, Asano S, et al. Efficacy of cefepime in the treatment of severe infections accompanying hematological diseases [in Japanese]. Antibiot Chemother 1999; 15:103-11.
14. Rubenstein EB, Kim YJ, Legha R, Rolston K, Multinational Association of Supportive Care in Cancer. Documented infections in febrile neutropenic patients presenting with apparent fever of undetermined origin: a wolf in sheep's clothing [abstract 5]. In: Program and abstracts of the 12th International synposium on Supportive Care in Cancer (Washington, DC). Supportive Care Cancer 2000; 8:242.